Novocure trial misses primary survival endpoint

• Novocure (NASDAQ:NVCR) reported that its Phase 3 TRIDENT trial for glioblastoma did not meet the primary endpoint of improved overall survival.
• The company's stock price experienced a significant decline following the announcement, trading down at $13.20.
• Novocure continues to analyze the trial data, citing the safety and feasibility of initiating Tumor Treating Fields therapy during chemoradiation.

Novocure (NASDAQ:NVCR) announced that its Phase 3 TRIDENT trial evaluating Tumor Treating Fields (TTFields) therapy for glioblastoma did not achieve a statistically significant improvement in overall survival.

The study compared initiating TTFields therapy alongside chemoradiation against starting the therapy during the subsequent maintenance phase, showing median overall survival of 17.7 months versus 17.5 months.

The trial enrolled 981 patients with a median age of 60 years and reported that 25% of participants failed to initiate the maintenance phase of treatment.

Novocure stated that the treatment was well-tolerated with no new safety signals reported, and it intends to share further analyses to inform future treatment approaches.

Novocure is an oncology company that focuses on the development of proprietary TTFields therapy for the treatment of various solid tumor cancers.

The company previously utilized its Optune device for glioblastoma treatment, which remains a cornerstone of its current product portfolio in the neuro-oncology market.